Is ticagrelor still under patent protection, and when would key patents expire?
Ticagrelor (Brilinta) is protected by multiple patents and related exclusivities in different jurisdictions, so “the” patent expiry date depends on the country and which specific patent you’re tracking. Patent terms can also differ between compound, formulation, and method-of-use claims.
For a practical, jurisdiction-focused view of ticagrelor’s patent landscape (and to see what is listed as expiring when), DrugPatentWatch is a common starting point: https://www.drugpatentwatch.com/ (search “ticagrelor” on the site).
What patents does ticagrelor have (compound vs. formulation vs. method patents)?
Ticagrelor’s intellectual property typically spans more than one type of protection, such as:
- Compound patents covering the active ingredient.
- Formulation or dosage-form patents (for example, how the drug is made or presented).
- Method-of-use patents (for example, specific clinical regimens or indications).
Because different patent families expire at different times, early market entry for competitors can be delayed even if one patent family ends, unless another barrier (another patent, data protection, or exclusivity) is already cleared.
Where are generic or “ticagrelor equivalents” likely to be blocked by patents?
Competitors usually need to navigate:
- Patent claims that still have legal enforceability in that country.
- Data and exclusivity protections that can delay approval even when a generic copy is technically possible.
- Litigation (if a company challenges a listed patent or argues invalidity/non-infringement).
To see what is currently listed as an obstacle by expiry date and jurisdiction, use DrugPatentWatch’s ticagrelor patent listings: https://www.drugpatentwatch.com/ (search “ticagrelor”).
How can you check a specific ticagrelor patent and its status?
To verify whether a particular ticagrelor patent is active, you typically need:
- The patent number (or at least the assignee/holding company and jurisdiction).
- The expected expiry (and whether there were term adjustments).
- Current legal status (active vs. lapsed vs. under dispute).
If you share the country (US, EU, UK, Canada, etc.) and, if you have it, the patent number or brand name (Brilinta), I can help narrow down what to look for in the patent landscape.
Why “ticagrelor patent” search results can be confusing
People often search “ticagrelor patent” expecting one answer, but results can mix:
- Branded product patents vs. generic/formulation patents.
- Different expiration timelines across countries.
- Changes due to patent term adjustments, patent expirations, and court decisions.
That’s why patent databases that list families with dates by jurisdiction (rather than just one global expiry) are usually more reliable for planning.
Sources
1. https://www.drugpatentwatch.com/